LSI.F CK Life Sciences Int'l. (Holdings) Inc
- Market cap
- EUR 581M
- P/E
- -
- P/B
- 1.28x
- ROE
- -4.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is LSI.F undervalued?
Graham numberThe Graham number of CK Life Sciences Int'l. (Holdings) Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CK Life Sciences Int'l. (Holdings) Inc fundamental analysis
No fundamental analysis for CK Life Sciences Int'l. (Holdings) Inc yet.
CK Life Sciences Int'l. (Holdings) Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CK Life Sciences Int'l. (Holdings) Inc
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, trades, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardenin…
Full company profileCK Life Sciences Int'l. (Holdings) Inc financial statements
CK Life Sciences Int'l. (Holdings) Inc annual financial statements (HKD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.87B | 4.69B | 5.23B | 4.97B | 4.94B | 5.40B | 5.28B | 5.32B | 5.52B | 5.41B |
| Gross Profit | 1.66B | 1.54B | 1.73B | 1.61B | 1.41B | 1.63B | 1.63B | 1.64B | 1.69B | 1.58B |
| Operating Income | 1.07B | 957M | 1.15B | 957M | 759M | 944M | 242M | 224M | 77.5M | -131M |
| EBITDA | - | 569M | 689M | 581M | 355M | 450M | 599M | 625M | 491M | 494M |
| Net Income | 252M | 258M | 263M | 182M | 125M | 163M | 132M | 17.3M | -127M | -187M |
| EPS | - | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | 0.01 | 0.00 | -0.01 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 9.54B | 10.6B | 10.4B | 10.7B | 12.0B | 11.7B | 11.3B | 11.2B | 10.8B | 11.8B |
| Total Liabilities | 5.08B | 5.83B | 6.02B | 6.54B | 7.26B | 7.23B | 7.11B | 7.06B | 7.28B | 7.99B |
| Shareholders' Equity | 4.31B | 4.62B | 4.26B | 4.18B | 4.72B | 4.50B | 4.16B | 4.19B | 3.51B | 3.78B |
| Cash & Short-term Investments | 859M | 1.04B | 773M | 697M | 959M | 891M | 692M | 664M | 554M | 603M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 439M | 135M | 231M | 379M | 531M | 424M | 364M | 514M | 354M | 187M |
| Capital Expenditure | 210M | 92.0M | 194M | 164M | 335M | 216M | 217M | 292M | 199M | 248M |
| Free Cash Flow | - | 40.1M | -57.1M | 181M | 151M | 206M | 147M | 222M | 154M | -61.0M |
| Ratios | ||||||||||
| ROE | 5.8% | 5.6% | 6.2% | 4.4% | 2.7% | 3.6% | 3.2% | 0.4% | -3.6% | -4.9% |
| ROA | 2.6% | 2.4% | 2.5% | 1.7% | 1.0% | 1.4% | 1.2% | 0.2% | -1.2% | -1.6% |
| Net Profit Margin | 5.2% | 5.5% | 5.0% | 3.7% | 2.5% | 3.0% | 2.5% | 0.3% | -2.3% | -3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CK Life Sciences Int'l. (Holdings) Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 23, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | HKD 76.9M | 0.01 | 445.7% |
| 2022 | EUR 96.1M | 0.01 | 72.8% |
| 2021 | EUR 96.1M | 0.01 | 59.0% |
| 2020 | EUR 96.1M | 0.01 | 76.7% |
| 2019 | EUR 96.1M | 0.01 | 52.9% |
| 2018 | EUR 96.1M | 0.01 | 36.5% |
| 2017 | EUR 96.1M | 0.01 | 37.2% |
| 2016 | EUR 86.5M | - | 34.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CK Life Sciences Int'l. (Holdings) Inc
- Insiders 74.98%
- Institutions 0.40%
- Public & others 24.62%
- Shares outstanding 9.61B
- Free float 2.40B
CK Life Sciences Int'l. (Holdings) Inc company profile
- Company name
- CK Life Sciences Int'l. (Holdings) Inc
- Ticker
- LSI.F
- ISIN
- KYG2176J1058
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,925
- Fiscal year end
- December
- Address
- 2 Dai Fu Street, Tai Po, Hong Kong
- Phone
- 852 2126 1212
- Website
- ck-lifesciences.com
About CK Life Sciences Int'l. (Holdings) Inc
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, trades, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines; supplies raw materials in nutritional health, pharmaceutical, cosmetics, personal care and food segments; financing activities; holding land and buildings; investment in financial instruments and vineyards; trading of biotechnology products and nutritional supplements; and manufacturing, wholesaling, retailing, and distribution of nutraceutical products. In addition, the company distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; and produces, refines, and distributes salt products. Further, it researches, develops, manufactures, and commercializes drug products to treat pain and melanoma; develops novel nonopioid therapeutics; supplies raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food sectors; and offers packing and asset management services. The company was founded in 1999 and is headquartered in Tai Po, Hong Kong.
CK Life Sciences Int'l. (Holdings) Inc management
10- Mr. Tzar Kuoi Li B.Sc., LLD, LLD (Hon), M.Sc.Executive Chairman · born 1964
- Mr. Ying Choi Yu MBACEO & Executive Deputy Chairman · born 1956
- Mr. Hing Lam Kam B.Sc., B.ScE, M.B.A.President & Executive Director · born 1946
- Mr. Tak Chuen IP B.A., M.Sc.Senior VP, Chief Investment Officer & Executive Director · born 1952
- Dr. Kean Meng Toh M.D., MBBSVP, Chief Scientific Officer & Executive Director · born 1967
- Mr. Wun Lam WongChief Financial Officer · born 1965
- Ms. Emily TanChief Operating Officer
- Ms. Yau Lin WongGeneral Manager of Human Resources & Administration · born 1967
- Ms. Ching Sze ChiuGeneral Counsel · born 1977
- Ms. Sze Mun HoVice President of Corporate Development · born 1972